DescriptionSources: https://www.rxlist.com/urocit-drug.htmCurator's Comment: Description was created based on several sources, including
http://www.adm.com/en-US/worldwide/australia/Documents/Potassium%20Citrate%20AU.pdf | https://noshly.com/additive/e332/acidity-regulator-plus/332/#.WUp-1uvyjIU
Sources: https://www.rxlist.com/urocit-drug.htm
Curator's Comment: Description was created based on several sources, including
http://www.adm.com/en-US/worldwide/australia/Documents/Potassium%20Citrate%20AU.pdf | https://noshly.com/additive/e332/acidity-regulator-plus/332/#.WUp-1uvyjIU
Potassium citrate is indicated for the management of renal tubular acidosis with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, uric acid lithiasis with or without calcium stones. WhenPotassium citrate is given orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate. Thus, potassium citrate therapy appears to increase urinary citrate principally by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. Potassium citrate is used as a food additive (E 332) to regulate acidity.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0010447 Sources: https://www.rxlist.com/urocit-drug.htm |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | UROCIT-K Approved UseUrocit®-K is a citrate salt of potassium indicated for the management of:
• Renal tubular acidosis (RTA) with calcium stones
• Hypocitraturic calcium oxalate nephrolithiasis of any etiology
• Uric acid lithiasis with or without calcium stones Launch Date1985 |
|||
| Primary | UROCIT-K Approved UseUrocit®-K is a citrate salt of potassium indicated for the management of:
• Renal tubular acidosis (RTA) with calcium stones
• Hypocitraturic calcium oxalate nephrolithiasis of any etiology
• Uric acid lithiasis with or without calcium stones Launch Date1985 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Evaluation of aggregating brain cell cultures for the detection of acute organ-specific toxicity. | 2013-06 |
|
| [Therapeutic use of potassium citrate]. | 2001 |
|
| Renal hypouricemia due to enhanced tubular secretion of urate associated with urolithiasis: successful treatment of urolithiasis by alkalization of urine K+, Na(+)-citrate. | 1993 |
|
| Comparative efficacy of "specific" potassium citrate therapy versus conservative management in nephrolithiasis of mild to moderate severity. | 1985-10 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.rxlist.com/urocit-drug.htm
Objective: To restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinarypH to a level of 6.0 to 7.0.• Severe hypocitraturia (urinary citrate < 150 mg/day): therapy should be initiated at 60 mEq per day; a dose of 30 mEq two times per day or 20 mEq three times per day with meals or within 30 minutes after meals or bedtime snack• Mild to moderate hypocitraturia (urinary citrate >150 mg/day): therapy should be initiated at 30 mEq per day; a dose of 15 mEq two times per day or 10 mEq three times per day with meals or within 30 minutes after meals or bedtime snack
Route of Administration:
Oral
| Substance Class |
Mixture
Created
by
admin
on
Edited
Mon Mar 31 18:29:18 GMT 2025
by
admin
on
Mon Mar 31 18:29:18 GMT 2025
|
| Record UNII |
1Q73Q2JULR
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Related Record | Type |
|---|
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QB05CB02
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
||
|
FDA ORPHAN DRUG |
87094
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
||
|
NCI_THESAURUS |
C29730
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
||
|
DSLD |
3850 (Number of products:9)
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
||
|
CFR |
21 CFR 184.1751
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
||
|
DSLD |
2694 (Number of products:90)
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
||
|
NCI_THESAURUS |
C263
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
||
|
WHO-ATC |
B05CB02
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB12582MIG
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
PRIMARY | |||
|
32142
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
PRIMARY | |||
|
253204
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
PRIMARY | |||
|
53258
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
PRIMARY | |||
|
CHEMBL1355
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
PRIMARY | |||
|
1Q73Q2JULR
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
PRIMARY | |||
|
C514290
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
PRIMARY | |||
|
C102006
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
PRIMARY | |||
|
C62075
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
PRIMARY | |||
|
1Q73Q2JULR
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
PRIMARY | |||
|
56466
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
ALTERNATIVE | |||
|
SUB16054MIG
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
PRIMARY | |||
|
TRISODIUM CITRATE
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
PRIMARY | |||
|
4477
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
PRIMARY | |||
|
DB09154
Created by
admin on Mon Mar 31 18:29:18 GMT 2025 , Edited by admin on Mon Mar 31 18:29:18 GMT 2025
|
PRIMARY |
One of these components may be present:
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SUB_CONCEPT->SUBSTANCE | |||
|
|
SUB_CONCEPT->SUBSTANCE |
|
||
|
|
SUB_CONCEPT->SUBSTANCE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|